We did not think the pan inhibitors were viable HDTs for TB however, since cancer clinical trials with the pan inhibitor ABT-263/navitoclax have been hampered due to toxicity concerns related to reduced platelet counts through inhibition of BCL-XL [11]. The gene discussed is BCL2L1; the disease is cancer.